Skip to main content

Advanced Search

Projected result for your current search:: 0

Search Operators:

You can use operators in your search query to narrow down your results even more. Click on the search operator to see an explanation of how it works.
Finds documents with exactly this word group, in exactly this word order and spelling (e.g. "employer branding").
Finds documents with both search terms (e.g. sales AND bonus).
Finds documents with one or the other search term (e.g. porsche OR volkswagen).
Finds documents with all search terms. Blank space is understood as AND (e.g. man robot production).
Finds documents with no appearance of the word behind NOT (e.g. ford NOT "harrison ford").
Finds documents where the search term is mentioned at least "n" times."n" may be any number (e.g. COUNT(gear)>8).
Finds documents with both search terms in any word order, permitting "n" words as a maximum distance between them. Best choose between 15 and 30 (e.g. NEAR(recruit, professionals, 20)).
Finds documents with the search term in word versions or composites. The asterisk * marks whether you wish them BEFORE, BEHIND, or BEFORE and BEHIND the search term (e.g. lightweight*, *lightweight, *lightweight*).
Finds documents with the search term in different spellings. "?" allows only one character (e.g. organi?ation).
Special characters are understood as AND (e.g. Miller Bros. & Sons).
 Log in
Top
Current Cardiology Reports

How to Optimize Goal-Directed Medical Therapy (GDMT) in Patients with Heart Failure

  • Open Access
  • 02-08-2024
  • Heart Failure
  • Heart Failure (HJ Eisen, Section Editor)
Published in:
Authors
Emily Newman
Chukwuemezie Kamanu
Gregory Gibson
Yevgeniy Brailovsky
Published in
Current Cardiology Reports | Issue 9/2024

Abstract

Purpose of Review

Heart failure is a clinical syndrome with signs and symptoms from underlying cardiac abnormality and evidence of pulmonary or systemic congestion on laboratory testing or other objective findings (Bozkurt et al. in Eur J Heart Fail 23:352–380, 2021). Heart failure with reduced ejection fraction (HFrEF), when heart failure is due to underlying reduction in ejection fraction to \(\le\) 40. The goal of this review is to briefly describe the mechanisms and benefits of the various pharmacological interventions described in the 2022 AHA/ACC/HFSA Guidelines focusing on Stage C: Symptomatic Heart Failure HFrEF, while providing basic guidance on safe use of these medications.

Recent Findings

Use of medications from each class as recommended in the 2022 Guidelines can provide significant morbidity and mortality benefits for our patients.

Summary

Despite advances in therapeutics for patients with HFrEF, patients are frequently under treated and more research is needed to help optimize management of these complicated patients.
Title
How to Optimize Goal-Directed Medical Therapy (GDMT) in Patients with Heart Failure
Authors
Emily Newman
Chukwuemezie Kamanu
Gregory Gibson
Yevgeniy Brailovsky
Publication date
02-08-2024
Publisher
Springer US
Published in
Current Cardiology Reports / Issue 9/2024
Print ISSN: 1523-3782
Electronic ISSN: 1534-3170
DOI
https://doi.org/10.1007/s11886-024-02101-x
This content is only visible if you are logged in and have the appropriate permissions.

Other articles of this Issue 9/2024

Hypertrophic Cardiomyopathy: From Medical Treatment to Advanced Heart Failure Therapies

Electrophysiological Cardiovascular Magnetic Resonance (EP-CMR)-Guided Interventional Procedures: Challenges and Opportunities

  • Atrial Flutter
  • Invasive Electrophysiology and Pacing (EK Heist and S Nedios, Section Editors)

Implementing a ‘Lead [Apron]-Free’ Cardiac Catheterization: Current Status

  • Open Access
  • Radiation Protection
  • New Therapies for Cardiovascular Disease (AA Bavry and MR Massoomi, Section Editors)

Cardiovascular Toxicity in Cancer Therapy: Protecting the Heart while Combating Cancer

Molecular Regulation of Cardiac Conduction System Development

  • Pacemaker
  • Regenerative Medicine (SM Wu, Section Editor)

Unraveling the Complex Relationship—Atrial Fibrillation and Pulmonary Hypertension

Next-generation MRI contrast agents: preparing the field (Link opens in a new window)

New MRI contrast agents are reshaping diagnostic imaging, promising lower gadolinium exposure amid evolving practice guidelines. How can you optimise contrast selection, dosing, and patient care in this rapidly advancing field?

This content is intended for healthcare professionals outside of the UK.

Independent Medical Education Grant:
  • Bayer HealthCare Pharmaceuticals Inc.
Learn more Link opens in a new window
Image Credits
Abstract graphic of layered, concentric circular shapes in bright green, pink, blue, and purple on a dark blue background. The rings and segments form a complex radial pattern without text/© Springer Health+ IME